Continuing our special focus on Biotech this week, we spoke to analyst Dr. Yaron Werber of Citi Investment Research, who talked a little bit about one of his pic in the Biotech space: Gilead Sciences (GILD).
Dr. Werber: Gilead is one of the well-known large cap biotech companies that is specifically playing in the HIV, hepatitis, and now in the pulmonary arterial hypertension (PAH) spaces. The reason to like Gilead, even though this company is fairly well understood, is that the sellside consensus estimates do not fully reflect the magnitude of growth that is still available globally to the HIV franchise. The growth is driven by organic market growth, geographical expansion and pricing.
We also believe that the company is highly focused so they have terrific leverage on expenses. We continue to believe that the bottom line numbers on the Street are too conservative and investors are not really looking at the ongoing operating margin expansion.
For the full interview with Dr. Werber, including a complete overview of his sector of coverage in the Biotech space and more stock picks, click here.
Gilead Sciences (GILD) Leads Biotech Large-Cap Innovation
September 17, 2012
Gilead (GILD) is a Biotech Bottom Buy According to Hartaj Singh of Oppenheimer & Company
August 19, 2022
Merck (MRK), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD) Trailblaze Hepatitis C Therapies
September 20, 2012
Gilead Sciences, Inc. (GILD) Leading the Charge in Hepatitis C Space with Shorter-Duration Drugs
April 26, 2013
A Pharma Pick for the Long Term: Gilead Sciences, Inc. (NASDAQ:GILD)
March 17, 2016